Oxford–AstraZeneca COVID-19 vaccine

GPTKB entity

Predicate	Object
gptkbp:instanceOf	vaccine
gptkbp:age	adults 18 years and older
gptkbp:alsoKnownAs	gptkb:ChAdOx1_nCoV-19 gptkb:Vaxzevria gptkb:AZD1222 gptkb:Covishield
gptkbp:approvedBy	December 2020
gptkbp:category	gptkb:University_of_Oxford gptkb:AstraZeneca gptkb:COVID-19_pandemic Vaccines 2020 introductions
gptkbp:clinicalTrialPhase	Phase III
gptkbp:countryOfOrigin	gptkb:United_Kingdom
gptkbp:developedBy	gptkb:University_of_Oxford gptkb:AstraZeneca gptkb:Vaccitech
gptkbp:distributionProgram	gptkb:COVAX
gptkbp:effect	about 70% (varies by study and dosing)
gptkbp:emergencyServices	gptkb:India gptkb:World_Health_Organization gptkb:UK_Medicines_and_Healthcare_products_Regulatory_Agency gptkb:European_Medicines_Agency many other countries
gptkbp:form	two doses
https://www.w3.org/2000/01/rdf-schema#label	Oxford–AstraZeneca COVID-19 vaccine
gptkbp:intervalBetweenDoses	4 to 12 weeks
gptkbp:manufacturer	gptkb:India gptkb:South_Korea gptkb:United_Kingdom other countries
gptkbp:notRecommendedFor	people with history of severe allergic reaction to vaccine ingredients
gptkbp:patent	gptkb:University_of_Oxford gptkb:AstraZeneca
gptkbp:routeOfAdministration	intramuscular injection
gptkbp:sideEffect	fatigue headache rare blood clotting events mild to moderate pain at injection site
gptkbp:storage	2–8°C
gptkbp:target	gptkb:COVID-19
gptkbp:vaccineType	viral vector vaccine
gptkbp:vectorFor	gptkb:chimpanzee_adenovirus
gptkbp:WHOModelListOfEssentialMedicines	included
gptkbp:bfsParent	gptkb:Covishield
gptkbp:bfsLayer	5